EVAX Evaxion Biotech

$EVAX FYI They have multiple events next 2weeks lol with 300k volume this stock moved over 20% as long as we already got decent data for a cancer vaccine there is a high chance to get massive pump like a wild animal..

$EVAX Bullish 🚀 Short Thesis on why this micro-cap explodes over the next 2-3 weeks. We are sitting right at a $2.90 base with a tiny $26M market cap. Shorts are completely trapped ahead of a massive data catalyst run. 1️⃣ ESMO 2026 (Oct 23-24): 3-year clinical update on the EVX-01 personalized melanoma cancer vaccine. If this shows long-term survival/efficacy data, a $26M cap is an absolute joke. 2️⃣ SITC 2026 (Nov 4-8): Follow-up oral presentation on the systemic immune data for EVX-01. Double-stamped validation. 3️⃣ Big Pharma Backing: Merck is already heavily involved here—disclosing a 1.21M share stake and just licensing the EVX-B3 candidate. They know the AI-Immunology platform is the real deal. Loaded up. The upside from a $2.90 entry towards the average analyst price target of $11.25+ is too big to ignore. Data is going to force a violent squeeze. 🔥📈 #Biotech #ShortSqueeze

$EVAX has reported durable three-year responses in its EVX-01 melanoma trial, with all patients maintaining benefit.

$EVAX Previous winner of International Prix Galien Award (2024 Exscientia) was sold at a value of 688 USDm - if Evaxion does the same that corresponds to a ADR price of ~76,3 USD.

$EVAX The ultimate validation isn't a Wall Street analyst; it's Merck, the world's leading oncology giant owning 10% of the company, the largest shareholder. 12/12 responders staying stable for 3 years is 1 in 60,000 odds by pure luck. The EDEN platform obviously works.

$EVAX is about to disrupt the entire oncology space! 🚀 While everyone is looking at Moderna's market cap, Evaxion Biotech is quietly weaponizing next-gen AI with their AI-Immunology™ platform. Predicting target neoantigens in just 24 hours is a massive logistical game-changer that traditional mRNA pipelines simply can't touch. The long-term data for EVX-01 proves the tech works. Smaller, faster, smarter—EVAX is going to outsmart and outrule MRNA in personalized cancer care. Bullish isn't even the word! 🧬💻🔥 #AI #Biotech #Bullish

$EVAX The data presentation is scheduled for this Friday. I think there's a strong chance we'll hear something about a potential partnership, and I wouldn't be surprised if a substantial amount of money comes in. Either way, the data looks extremely promising. $MRNA $BNTX $MRK

$EVAX The market is valuing $EVAX like a single-trick pony, completely missing the bigger picture. Melanoma success is just the clinical proof of concept. This is a true platform drug powered by AI—one codebase to target dozens of solid tumors. When Big Pharma realizes the scalability of EVX-01/05, this flies. 💎🙌🔥

$EVAX I like the slow, consistent move upwards going into next week. Can't imagine how this will move when volume finds it. Feeling October 2025 vibes again...

$EVAX — the big one is this Saturday, **October 24**: they're presenting the full three-year EVX-01 melanoma data as a poster at ESMO (the European oncology conference). That's the detailed data behind yesterday's press release, so it could move the stock either way depending on how the details look. Then next Thursday, **October 29**, they're hosting a webinar with the study's lead investigator walking through the findings and taking questions.

$EVAX this may not make a major move until later this week or next. As others have mentioned, partnership is the real goal here...not holding my breath for an announcement next week on that, but it would be a pleasant surprise. Cash runway to 2H27 is helpful to reduce likelihood of dilution.

$EVAX On one hand, i would not have been surprised if the 2 year data were showing pembro alone; pembro responses tend to deepen over time. So maybe. As we have seen in other trials, T-cell production doesn’t have to translate to efficacy. So another hopeful sign but another weak maybe. Three year presentation is another maybe but aslo adds a little more to the case for evx efficacy. It will be interesting to see if a partner is found.

$EVAX it's all about finding a partnership to take them into phase 3 trials. No partner...no phase 3. 89% is great, just need one of the big boys to pick them up for the next steps. Oh...and F$@# Cancer.

$EVAX presented three-year EVX-01 data with 89% target precision and sustained T-cell responses in advanced melanoma.

$EVAX I don’t get why this stock is selling off. ESMO is just a few days away, and you’d think the stock would be moving up, not down. I get that some people wanted to take profits, but the timing just doesn’t make sense to me.

$EVAX In your opinion, could the November 9 SITC event be a meaningful catalyst for the stock? Or will they simply be presenting the same data we already saw at ESMO and discussed again during the recent webinar, which had no impact on the share price whatsoever?

$EVAX let get some sunshine for the investors - someone should call up their IR team and tell them to share good news

ICMB keep this on watch for Monday/strong close. ICMB: -Fair value at $3.44.💎 -low float.💎 -clean/no dilution ever💎 -Positive cash flow/$1.44 cash per share.💎 -161 Million in asset.💎 -Possible Acquisition or merger catalyst.💎 $EVAX $NIXX $IRON $SNES :))./

$EVAX I’ve been in EVAX for six months. The data are finally out, and they’re positive. So here’s my dilemma: the posters are coming out soon, on Saturday, and the stock could still move up a bit. But I think that if any major partnership news comes out during the webinars, the stock could run much higher than where it is now. Is this just a crazy take, or does my reasoning make sense?

EVAX Stock Heads For Best Week Since January 2025 As Cancer Vaccine Shows 89% Target Precision $EVAX $XBI https://stocktwits.com/news/equity/markets/evax-stock-evaxion-cancer-vaccine-target-precision/cZxygBbRBxO